Logo image of AZYO

AZIYO BIOLOGICS INC-CLASS A (AZYO) Stock Fundamental Analysis

NASDAQ:AZYO - Nasdaq - US05479K1060 - Common Stock - Currency: USD

1.49  +0.03 (+2.05%)

Fundamental Rating

1

AZYO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. AZYO has a bad profitability rating. Also its financial health evaluation is rather negative. AZYO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AZYO has reported negative net income.
In the past year AZYO has reported a negative cash flow from operations.
AZYO had negative earnings in each of the past 5 years.
In the past 5 years AZYO always reported negative operating cash flow.
AZYO Yearly Net Income VS EBIT VS OCF VS FCFAZYO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

AZYO has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AZYO Yearly ROA, ROE, ROICAZYO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 200 400 600

1.3 Margins

Looking at the Gross Margin, with a value of 35.86%, AZYO is in the better half of the industry, outperforming 75.90% of the companies in the same industry.
AZYO's Gross Margin has declined in the last couple of years.
AZYO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.35%
GM growth 5YN/A
AZYO Yearly Profit, Operating, Gross MarginsAZYO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

0

2. Health

2.1 Basic Checks

AZYO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AZYO has more shares outstanding
The debt/assets ratio for AZYO is higher compared to a year ago.
AZYO Yearly Shares OutstandingAZYO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M
AZYO Yearly Total Debt VS Total AssetsAZYO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -4.75, we must say that AZYO is in the distress zone and has some risk of bankruptcy.
AZYO's Altman-Z score of -4.75 is on the low side compared to the rest of the industry. AZYO is outperformed by 66.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.75
ROIC/WACCN/A
WACC16.57%
AZYO Yearly LT Debt VS Equity VS FCFAZYO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.84 indicates that AZYO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.84, AZYO is doing worse than 92.99% of the companies in the same industry.
A Quick Ratio of 0.63 indicates that AZYO may have some problems paying its short term obligations.
With a Quick ratio value of 0.63, AZYO is not doing good in the industry: 94.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.63
AZYO Yearly Current Assets VS Current LiabilitesAZYO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.95% over the past year.
AZYO shows a small growth in Revenue. In the last year, the Revenue has grown by 4.13%.
Measured over the past years, AZYO shows a small growth in Revenue. The Revenue has been growing by 4.66% on average per year.
EPS 1Y (TTM)22.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.8%
Revenue 1Y (TTM)4.13%
Revenue growth 3Y4.66%
Revenue growth 5YN/A
Sales Q2Q%-18.53%

3.2 Future

AZYO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.99% yearly.
Based on estimates for the next years, AZYO will show a small growth in Revenue. The Revenue will grow by 2.27% on average per year.
EPS Next Y9.47%
EPS Next 2Y17.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.95%
Revenue Next 2Y2.27%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZYO Yearly Revenue VS EstimatesAZYO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AZYO Yearly EPS VS EstimatesAZYO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AZYO. In the last year negative earnings were reported.
Also next year AZYO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AZYO Price Earnings VS Forward Price EarningsAZYO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AZYO Per share dataAZYO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as AZYO's earnings are expected to grow with 17.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.99%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AZYO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AZIYO BIOLOGICS INC-CLASS A

NASDAQ:AZYO (9/6/2023, 8:00:01 PM)

1.49

+0.03 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners74.28%
Inst Owner Change9.26%
Ins Owners3.94%
Ins Owner Change0%
Market Cap24.21M
Analysts82.86
Price Target8.16 (447.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-54.35%
Min EPS beat(2)-119.74%
Max EPS beat(2)11.04%
EPS beat(4)2
Avg EPS beat(4)-17.6%
Min EPS beat(4)-119.74%
Max EPS beat(4)46.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.93%
Min Revenue beat(2)-19.25%
Max Revenue beat(2)-6.61%
Revenue beat(4)0
Avg Revenue beat(4)-7.19%
Min Revenue beat(4)-19.25%
Max Revenue beat(4)-1.06%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)-133.33%
EPS NQ rev (3m)-55.56%
EPS NY rev (1m)-76.03%
EPS NY rev (3m)-33.12%
Revenue NQ rev (1m)48.44%
Revenue NQ rev (3m)-36.24%
Revenue NY rev (1m)12.37%
Revenue NY rev (3m)-27.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS2.98
BVpS-1.36
TBVpS-2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.86%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.35%
GM growth 5YN/A
F-Score3
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.74%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.63
Altman-Z -4.75
F-Score3
WACC16.57%
ROIC/WACCN/A
Cap/Depr(3y)13.65%
Cap/Depr(5y)12.19%
Cap/Sales(3y)1.13%
Cap/Sales(5y)1.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.8%
EPS Next Y9.47%
EPS Next 2Y17.99%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.13%
Revenue growth 3Y4.66%
Revenue growth 5YN/A
Sales Q2Q%-18.53%
Revenue Next Year-12.95%
Revenue Next 2Y2.27%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.81%
OCF growth 3YN/A
OCF growth 5YN/A